These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 16925991

  • 1. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S, Jackson MJ, Smith LA, Stockwell K, Johnson L, Carminati P, Jenner P.
    Eur J Pharmacol; 2006 Sep 28; 546(1-3):82-7. PubMed ID: 16925991
    [Abstract] [Full Text] [Related]

  • 2. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P.
    Mov Disord; 2004 Jan 28; 19(1):15-21. PubMed ID: 14743355
    [Abstract] [Full Text] [Related]

  • 3. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
    Tronci E, Simola N, Borsini F, Schintu N, Frau L, Carminati P, Morelli M.
    Eur J Pharmacol; 2007 Jul 02; 566(1-3):94-102. PubMed ID: 17445798
    [Abstract] [Full Text] [Related]

  • 4. The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
    Rose S, Ramsay Croft N, Jenner P.
    Brain Res; 2007 Feb 16; 1133(1):110-4. PubMed ID: 17196564
    [Abstract] [Full Text] [Related]

  • 5. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P.
    Exp Neurol; 2000 Apr 16; 162(2):321-7. PubMed ID: 10739638
    [Abstract] [Full Text] [Related]

  • 6. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK, Banerji T, Jenner P, Marsden CD.
    Mov Disord; 1998 Mar 16; 13(2):234-41. PubMed ID: 9539335
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Johnston TH, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM.
    J Pharmacol Exp Ther; 2010 Jun 16; 333(3):865-73. PubMed ID: 20231306
    [Abstract] [Full Text] [Related]

  • 11. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.
    Synapse; 2006 Sep 01; 60(3):239-50. PubMed ID: 16739115
    [Abstract] [Full Text] [Related]

  • 12. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
    Tayarani-Binazir KA, Jackson MJ, Fisher R, Zoubiane G, Rose S, Jenner P.
    Eur J Pharmacol; 2010 Jun 10; 635(1-3):109-16. PubMed ID: 20303948
    [Abstract] [Full Text] [Related]

  • 13. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys.
    Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P.
    Ann Neurol; 1998 Apr 10; 43(4):507-13. PubMed ID: 9546333
    [Abstract] [Full Text] [Related]

  • 14. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
    Uchida S, Soshiroda K, Okita E, Kawai-Uchida M, Mori A, Jenner P, Kanda T.
    Eur J Pharmacol; 2015 Jan 15; 747():160-5. PubMed ID: 25499739
    [Abstract] [Full Text] [Related]

  • 15. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
    Pinna A, Tronci E, Schintu N, Simola N, Volpini R, Pontis S, Cristalli G, Morelli M.
    Neuropharmacology; 2010 Mar 15; 58(3):613-23. PubMed ID: 19951715
    [Abstract] [Full Text] [Related]

  • 16. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
    Smith LA, Jackson MJ, Hansard MJ, Maratos E, Jenner P.
    Mov Disord; 2003 May 15; 18(5):487-95. PubMed ID: 12722161
    [Abstract] [Full Text] [Related]

  • 17. Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.
    Kuoppamäki M, Al-Barghouthy G, Jackson M, Smith L, Zeng BY, Quinn N, Jenner P.
    Mov Disord; 2002 Nov 15; 17(6):1312-7. PubMed ID: 12465074
    [Abstract] [Full Text] [Related]

  • 18. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
    Hill MP, Ravenscroft P, McGuire SG, Brotchie JM, Crossman AR, Rochat C, Millan MJ.
    Mov Disord; 2006 Dec 15; 21(12):2090-5. PubMed ID: 16991143
    [Abstract] [Full Text] [Related]

  • 19. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
    Pinna A, Pontis S, Borsini F, Morelli M.
    Synapse; 2007 Aug 15; 61(8):606-14. PubMed ID: 17476684
    [Abstract] [Full Text] [Related]

  • 20. Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.
    Tayarani-Binazir KA, Jackson MJ, Rose S, Olanow CW, Jenner P.
    Mov Disord; 2010 Feb 15; 25(3):377-84. PubMed ID: 20108359
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.